Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Analysis updated November 9, 2026
The CGT Access Model's most consequential design choice is the federal monopsony negotiation structure. By positioning CMS as the single counterparty to Vertex Pharmaceuticals and Genetix Biotherapeutics (formerly bluebird bio for Lyfgenia), CMMI has created what no individual state Medicaid agency could: a negotiating bloc representing 84% of Medicaid beneficiaries with SCD aged 12 and older across 34 state/territory programs. This is architecturally distinct from every prior CMMI model — it is not a delivery reform or payment methodology shift, but a direct federal price intervention operating through the supplemental rebate mechanism.
The first evaluation report (covering March 2024–December 2025) confirms the design produced its intended leverage effect: CMS secured outcomes-based rebates, volume-based rebates, guaranteed rebates, and a manufacturer-funded fertility preservation benefit that individual states could not have negotiated independently. Critically, the evaluation found that states lacking resources or prior VBP experience benefited disproportionately — precisely the states with no alternative path to an OBA for a $2.2–3.1 million therapy.
The 11-year performance period (PY1: January 1, 2025 through December 31, 2035) with an OBA Term capped at 6 years (through approximately December 31, 2030) creates a structural tension: states are bound to data collection and reporting obligations through 2035 even after the rebate-generating period closes. This tail obligation — roughly 5 years of registry participation, outcome tracking, and reporting with no corresponding rebate upside — represents a real administrative cost that program administrators must budget explicitly.
The 340B exclusion is a hidden operational tripwire. The Billing Information Guide confirms that because gene therapy for SCD is administered inpatient, the 340B program does not apply — even though these drugs are classified as "covered outpatient drugs" for MDRP purposes. For safety-net hospitals that routinely rely on 340B savings to cross-subsidize operations, this eliminates a potential offset they might have assumed would exist, increasing the effective net acquisition cost of administering these therapies.
The fertility preservation safe harbor (under 42 CFR §1001.952(ii)) is architecturally elegant: it shifts what would otherwise be a Medicaid-covered (or uncovered) benefit onto manufacturers, reduces state FFP claims, and creates precedent for manufacturer-funded adverse-effect mitigation. If CMS expands this model to other CGT indications — which the model page explicitly anticipates — this safe harbor structure becomes the template for how manufacturers fund collateral care.
States and health systems should approach CGT Access economics through three lenses: therapy cost exposure, rebate structure, and administrative investment.
Therapy Cost Exposure: Casgevy's list price is $2.2 million per dose; Lyfgenia's is $3.1 million. The OBA's negotiated rebates reduce net cost, but the model does not publicly disclose the specific rebate percentages. Even assuming a 20–30% blended rebate (consistent with aggressive Medicaid VBP arrangements for other high-cost therapies), state net cost per patient remains in the range of $1.5–2.5 million for the drug alone, exclusive of:
A reasonable total episode cost estimate — drug plus care journey — runs $3–5 million per patient in the first two years, even net of model rebates. For high-SCD-burden states (California, New York, Texas, North Carolina, Illinois — all participating), even 10–20 patients per year creates nine-figure annual exposure before rebates flow back.
Rebate Timing Risk: The reconciliation structure — outcomes measured over a multi-year Measurement Period with final settlement occurring in a Reconciliation Period after the Measurement Period concludes — means states incur the full acquisition cost upfront and recover outcome-based rebates years later. In the Figure 1 example from the RFA, a cohort treated in PY1 would not reach final reconciliation until PY3 or later. States must carry the full working capital exposure on $2.2–3.1 million per-patient drug costs for multiple years, creating a cash flow liability that Medicaid program finance offices have no historical precedent for managing.
Administrative Cost Floor: States awarded Cooperative Agreement funding (Connecticut, DC, Illinois, Mississippi, North Carolina, Pennsylvania, Rhode Island, Vermont) have partial offset. The eight non-competitive awardees represent mostly smaller or high-SCD-burden states where CMS correctly identified resource gaps. The 26 remaining participating states bear full administrative cost for registry compliance, managed care contract amendments, billing instruction development, SPA approvals, and outcome data collection — without cooperative agreement subsidy.
Treatment Centers: The model creates a durable competitive moat for the small number of qualified SCD gene therapy treatment centers. States must contract with at least one center (in-state or out-of-state) by PY2 (January 1, 2026) and maintain that contract through the OBA Term. Centers that achieve CIBMTR membership and CGT Access model recognition effectively become mandatory contracting partners for 34 state Medicaid programs. This is not a volume play — SCD gene therapy volumes will remain small — but a strategic positioning play. The limited number of qualified sites means centers administering Casgevy or Lyfgenia hold significant leverage in rate negotiations with states under 42 CFR §431.52 out-of-state provider requirements.
Large Academic Medical Centers and Children's Hospitals: These institutions are structurally advantaged. They have existing bone marrow transplant infrastructure, CIBMTR membership, hematology subspecialty depth, and the financial capacity to absorb the capital requirements of gene therapy administration. Community hospitals and rural systems are effectively excluded from participation — not by model design, but by the resource requirements of administering a therapy with a 35–45-day inpatient infusion/recovery component.
Medicaid Managed Care Organizations: MCOs in participating states face a complex alignment burden. States must either carve CGT drugs out of managed care contracts or align MCO coverage policies, prior authorization criteria, and claims processing with model requirements by January 1, 2026. The continuity-of-care requirements — honoring prior authorizations across plan switches, maintaining provider access for at least one year post-infusion — create administrative obligations MCOs have not previously managed for million-dollar single-dose therapies. MCOs that carve out the drug still retain responsibility for all associated inpatient and outpatient services, meaning they bear the care journey cost while the state manages the drug rebate.
Medicare Advantage Plans: CGT Access has no direct MA application — it operates exclusively in Medicaid. However, MA plans covering dual-eligibles with SCD should monitor the model's outcomes data closely. If 15-year follow-up data demonstrates durable efficacy (reduction in VOCs, hospitalizations, emergency department utilization), the downstream cost savings case for MA coverage of CGT — currently not subject to OBAs — will strengthen considerably.
Physician/Hematologist Perspective: SCD specialists face new administrative requirements without corresponding revenue enhancement. CIBMTR registry participation, patient consent documentation for the CMS-sponsored study, and model-specific claims submission requirements add workflow burden. The upside: the model's standardized access policy is explicitly designed to be no more restrictive than negotiated criteria, meaning physicians should face fewer prior authorization denials than under independent state policies. The model also funds case management and care coordination infrastructure that historically fell on physician practice staff.
Health System Perspective: Systems with qualified SCD gene therapy programs face a strategic decision: invest in the infrastructure to become a model-designated treatment center and capture 34-state Medicaid referral flow, or remain outside the model. The investment threshold is real — CIBMTR membership, specialized nursing capacity for 35–45-day gene therapy inpatient stays, and data reporting infrastructure are not trivial. But the competitive moat for early movers is significant. The model's reimbursement requirement (no less than actual acquisition cost) protects systems from below-cost drug reimbursement, a concern that deterred some institutions from early CGT adoption.
Hospital Finance Perspective: The inpatient DRG carveout requirement is the pivotal finance issue. States must carve CGT drugs out of DRG bundled payments and reimburse directly. This is operationally beneficial for hospitals — they receive separate drug reimbursement at acquisition cost rather than having a $2.2–3.1 million drug absorbed into a fixed DRG payment — but it requires hospitals to submit model-compliant claims with specific NDC and HCPCS codes, and to document acquisition cost. Hospital revenue cycle teams unfamiliar with Medicaid outpatient drug billing for inpatient-administered therapies will need targeted training.
Payer/MA Plan Perspective: The model's first evaluation report explicitly identifies expansion to other CGT indications as a design goal. Payers should treat CGT Access as a policy prototype, not an isolated Medicaid sickle cell program. The precedent of federal OBA negotiation on behalf of state Medicaid programs — with manufacturer-funded collateral benefits (fertility preservation), centralized outcome measurement, and standardized access policy — is directly transferable to hemophilia gene therapies, Duchenne muscular dystrophy treatments, and other high-cost CGTs in active FDA review pipelines. Plans that build internal capability to evaluate OBA structures now will be positioned to negotiate analogous arrangements when those therapies reach market.
The CGT Access Model's first evaluation report signals CMMI's intent to expand this framework. The model page confirms CMMI is "broadening the framework" following positive initial results. For state Medicaid programs, health systems with transplant infrastructure, and payers tracking CGT pipeline risk, the window to build operational readiness is open — but narrow.